Krina K. Patel - Concepedia

Author

Krina K. Patel

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Dipani Patel, Dr. Krina Patel, K K Patel, K. Patel, KRINA patel, Kenna Martin, Krina K. Patel, Krina D Patel, Krina K Patel, Krina K. Patel

540

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Moffitt Cancer Center Stanford University Levine Cancer Institute Huntsman Cancer Institute

About

Krina K. Patel is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell transplantation, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	27	597
2	Health Sciences	10	10	185
3	Public Health	3	3	61
4	Business	1	1	18
5	Engineering	1	1	14

Krina K. Patel

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf, New England Journal of Medicine	2023	627
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Journal of Clinical Oncology	2023	257
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma Nina Shah, Li Li, Jessica M McCarty, British Journal of Haematology	2017	217
Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) Tara Gregory, Adam D. Cohen, Caitlin Costello, Blood	2018	104
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial Qaiser Bashir, Peter F. Thall, Denái R. Milton, The Lancet Haematology Hematological MalignancyTransplantationMedicineMelphalan Versus MelphalanImmunology	2019	100
ATF-4 and hydrogen sulfide signalling mediate longevity in response to inhibition of translation or mTORC1 Cyril Statzer, Meng Jin, Richard Venz, Nature Communications	2022	99
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi, Blood Cancer Journal	2023	96
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma Surbhi Sidana, Krina K. Patel, Lauren C. Peres, Blood	2024	92
Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies Caitlin Costello, Adam D. Cohen, Krina K. Patel, Blood	2020	76
Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) Caitlin Costello, Tara Gregory, Syed Abbas Ali, Blood	2019	53

Page 1